Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year
22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 MPOSITIVE MOMENTUM AND OUTLOOK FOR 2023DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDUSTRYHAMBURG